Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.55 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.49 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.49 |
| ▸ | BCHE | P06276 | 2/20 | 0.47 |
| ▸ | NAAA | Q02083 | 3/20 | 0.46 |
| ▸ | SLC18A3 | Q16572 | 2/20 | 0.44 |
| ▸ | CNR1 | P21554 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21638171 | 1.00 | LIPG (0.55) | LIPGCARM1PRMT6BCHENAAA | |
| SCHEMBL4013732 | 0.92 | CARM1 (0.54) | LIPGCARM1PRMT6BCHENAAA | |
| SCHEMBL16422780 | 0.88 | NAAA (0.54) | LIPGCARM1PRMT6BCHENAAA | |
| SCHEMBL16600562 | 0.88 | LIPG (0.51) | LIPGCARM1PRMT6BCHENAAA | |
| SCHEMBL18426023 | 0.87 | GRIN2D (0.52) | LIPGCARM1PRMT6BCHENAAA | |
| SCHEMBL2526379 | 0.87 | GRIN2D (0.52) | LIPGCARM1PRMT6BCHENAAA | |
| SCHEMBL2525766 | 0.87 | GRIN2D (0.52) | LIPGCARM1PRMT6BCHENAAA | |
| SCHEMBL21723006 | 0.86 | CARM1 (0.49) | LIPGCARM1PRMT6BCHENAAA | |
| SCHEMBL2459133 | 0.86 | MGLL (0.49) | LIPGCARM1PRMT6BCHE | |
| SCHEMBL5809457 | 0.86 | CARM1 (0.49) | LIPGCARM1PRMT6BCHENAAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110475775-B | 4-pyridone compound or salt thereof, pharmaceutical composition containing 4-pyridone compound, and agent | 富士胶片株式会社 | 2023-05-09 | — | — | CN | disclosed |
| US-11161830-B2 | 4-pyridone compound or salt thereof, and pharmaceutical composition and formulation including same | FUJIFILM CORPORATION (JP) | 2021-11-02 | — | — | US | disclosed |
| EP-3604301-B1 | 4-PYRIDONE COMPOUND OR SALT THEREOF, AND PHARMACEUTICAL COMPOSITION AND FORMULATION INCLUDING SAME | FUJIFILM CORP (JP) | 2021-09-22 | — | — | EP | disclosed |
| EP-3604301-A1 | 4-PYRIDONE COMPOUND OR SALT THEREOF, AND PHARMACEUTICAL COMPOSITION AND FORMULATION INCLUDING SAME | FUJIFILM Corporation (JP) | 2020-02-05 | — | — | EP | disclosed |
| US-9850203-B2 | Autotaxin inhibitor compounds | PHARMAKEA, INC. (US) | 2017-12-26 | — | — | US | disclosed |
| EP-3049405-A1 | AUTOTAXIN INHIBITOR COMPOUNDS | Pharmakea Inc. (US) | 2016-08-03 | — | — | EP | disclosed |
| US-20160214935-A1 | AUTOTAXIN INHIBITOR COMPOUNDS | DF 2024 IP ACQUISITION, LLC | 2016-07-28 | — | — | US | disclosed |
| WO-2015048301-A1 | AUTOTAXIN INHIBITOR COMPOUNDS | PHARMAKEA, INC. (US) | 2015-04-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11161830-B2 | 4-pyridone compound or salt thereof, and pharmaceutical composition and formulation including same | HAVCR2, HBS1L, PHKB | LIPG 4820/4885CARM1 2911/4885PRMT6 1138/4885 |
| US-20160214935-A1 | AUTOTAXIN INHIBITOR COMPOUNDS | ENPP2, SERPINB1, SERPINE1 | LIPG 1003/4885CARM1 4495/4885PRMT6 3359/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.